Potency assessment of IFNγ-producing SARS-CoV-2-specific T cells from COVID-19 convalescent subjects
Rubén Gil-Bescós1, Ainhoa Ostiz1, Saioa Zalba2
1Oncohematology Research Group, Navarrabiomed, University Hospital of Navarra, Public University of Navarra, Navarra Medical Research Institute (IdiSNA), Pamplona, Spain.
Abstract:
The development of new therapies for COVID-19 high-risk patients remains necessary to prevent additional deaths. Here, we studied the phenotypical and functional characteristics of IFN-γ producing-SARS-CoV-2-specific T cells (SC2-STs), obtained from 12 COVID-19 convalescent donors, to determine their potency as an off-the-shelf T cell therapy product. We found that these cells present mainly an effector memory phenotype, characterized by the basal expression of cytotoxicity and activation markers, including granzyme B, perforin, CD38, and PD-1. We demonstrated that SC2-STs could be expanded and isolated in vitro, and they exhibited peptide-specific cytolytic and proliferative responses after antigenic re-challenge. Collectively, these data demonstrate that SC2-STs can be a suitable candidate for the manufacture of a T cell therapy product aimed to treat severe COVID-19.
